{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T16:12:50Z","timestamp":1781971970221,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["SA1360\/7-3"],"award-info":[{"award-number":["SA1360\/7-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"crossref","award":["2007.115.3"],"award-info":[{"award-number":["2007.115.3"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"crossref","award":["111828"],"award-info":[{"award-number":["111828"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"crossref","award":["70113496"],"award-info":[{"award-number":["70113496"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70112914"],"award-info":[{"award-number":["70112914"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Germany's Excellence Strategy","award":["EXC 2180\/1"],"award-info":[{"award-number":["EXC 2180\/1"]}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several genetic and clinical markers are established as prognostic factors in chronic lymphocytic leukemia (CLL). However, additional markers are needed for risk stratification. Flow cytometric analysis is a mainstay of CLL diagnostics, thus identification of novel prognostic surface markers can improve risk assessment without increasing burden for patients and physicians. Furthermore, surface molecules preferentially expressed in high-risk cases could serve as therapeutic targets for immunotherapy. CD105 (endoglin) is a TGF-beta coreceptor and activates endothelial cells in healthy tissues and cancer. In addition, it is expressed on healthy hematopoietic precursors as well as lymphoid and myeloid leukemias. In acute myeloid leukemia (AML), a CD105 antibody is successfully applied in clinical studies. In CLL, mRNA expression of the CD105 gene ENG reportedly correlates with other risk factors but failed to show significant correlation with overall survival. However, CD105 protein expression in CLL has never been studied. We here analyzed CD105 surface expression on CLL cells from 71 patients by flow cytometry and report for the first time that substantial levels of CD105 are detectable on CLL cells in 70.4% of patients. Using receiver operating characteristics, we established a cutoff of 5.99% positive cells to distinguish between low and high CD105 levels, the latter correlating with decreased time to first treatment and overall survival. High CD105 expression further correlates with CD38 expression. Our study identified membrane expression of CD105 as a potential risk marker and therapeutic target in high-risk CLL. However, multivariant analyses of large cohorts should be performed in confirmatory studies.<\/jats:p>","DOI":"10.1007\/s00277-022-04756-4","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T08:03:22Z","timestamp":1642579402000},"page":"773-780","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of CD105 (endoglin) as novel risk marker in CLL"],"prefix":"10.1007","volume":"101","author":[{"given":"Sarah M.","family":"Greiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"M\u00e4rklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Holzmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra","family":"Kaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Hinterleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Hagelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundram","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas S.","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-0167","authenticated-orcid":false,"given":"Joseph","family":"Kauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"issue":"2","key":"4756_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/leu.2014.196","volume":"29","author":"P Baliakas","year":"2015","unstructured":"Baliakas P et al (2015) Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 29(2):329\u2013336","journal-title":"Leukemia"},{"key":"4756_CR2","unstructured":"Rai K (1987) A critical analysis of staging in CLL. Chronic Lymphocytic Leuk Recent Prog Future Dir: 253\u2013264"},{"issue":"2","key":"4756_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0889-8588(18)30497-0","volume":"4","author":"KR Rai","year":"1990","unstructured":"Rai KR, Han T (1990) Prognostic factors and clinical staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 4(2):447\u2013456","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"4756_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","volume":"48","author":"J Binet","year":"1981","unstructured":"Binet J et al (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48(1):198\u2013206","journal-title":"Cancer"},{"issue":"2","key":"4756_CR5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/1097-0142(197708)40:2<855::AID-CNCR2820400239>3.0.CO;2-1","volume":"40","author":"J Binet","year":"1977","unstructured":"Binet J et al (1977) A clinical staging system for chronic lymphocytic leukemia. Prognostic significance. Cancer 40(2):855\u2013864","journal-title":"Cancer"},{"issue":"1","key":"4756_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/leu.2012.216","volume":"27","author":"A Rawstron","year":"2013","unstructured":"Rawstron A et al (2013) Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 27(1):142\u2013149","journal-title":"Leukemia"},{"issue":"5","key":"4756_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"A Rawstron","year":"2007","unstructured":"Rawstron A et al (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21(5):956\u2013964","journal-title":"Leukemia"},{"issue":"3","key":"4756_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00277-013-1967-y","volume":"93","author":"G Brachtl","year":"2014","unstructured":"Brachtl G et al (2014) The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Ann Hematol 93(3):361\u2013374","journal-title":"Ann Hematol"},{"issue":"6","key":"4756_CR9","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","volume":"94","author":"RN Damle","year":"1999","unstructured":"Damle RN et al (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia: presented in part at the 40th Annual Meeting of The American Society of Hematology, held in Miami Beach, FL, December 4\u20138, 1998. Blood 94(6):1840\u20131847","journal-title":"Blood"},{"issue":"9403","key":"4756_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","volume":"363","author":"JA Orchard","year":"2004","unstructured":"Orchard JA et al (2004) ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363(9403):105\u2013111","journal-title":"Lancet"},{"issue":"6","key":"4756_CR11","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.leukres.2010.10.022","volume":"35","author":"A Majid","year":"2011","unstructured":"Majid A et al (2011) CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res 35(6):750\u2013756","journal-title":"Leuk Res"},{"issue":"2","key":"4756_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1074\/jbc.274.2.584","volume":"274","author":"NP Barbara","year":"1999","unstructured":"Barbara NP, Wrana JL, Letarte M (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-\u03b2 superfamily. J Biol Chem 274(2):584\u2013594","journal-title":"J Biol Chem"},{"issue":"20","key":"4756_CR13","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1038\/sj.emboj.7600386","volume":"23","author":"F Lebrin","year":"2004","unstructured":"Lebrin F et al (2004) Endoglin promotes endothelial cell proliferation and TGF-\u03b2\/ALK1 signal transduction. EMBO J 23(20):4018\u20134028","journal-title":"EMBO J"},{"issue":"6","key":"4756_CR14","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.4049\/jimmunol.141.6.1925","volume":"141","author":"A Gougos","year":"1988","unstructured":"Gougos A, Letarte M (1988) Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 141(6):1925\u20131933","journal-title":"J Immunol"},{"issue":"12","key":"4756_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1440-1827.2006.02037.x","volume":"56","author":"R Minhajat","year":"2006","unstructured":"Minhajat R et al (2006) Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers. Pathol Int 56(12):717\u2013723","journal-title":"Pathol Int"},{"issue":"12","key":"4756_CR16","first-page":"1623","volume":"1","author":"FJ Burrows","year":"1995","unstructured":"Burrows FJ et al (1995) Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1(12):1623\u20131634","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4756_CR17","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1309\/X6NXYE57DLUE2NQ8","volume":"127","author":"YM El-Gohary","year":"2007","unstructured":"El-Gohary YM et al (2007) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 127(4):572\u2013579","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"4756_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/01.PGP.0000070852.25718.37","volume":"22","author":"RS Saad","year":"2003","unstructured":"Saad RS et al (2003) Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol 22(3):248\u2013253","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"4756_CR19","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/pros.10083","volume":"51","author":"P Wikstr\u00f6m","year":"2002","unstructured":"Wikstr\u00f6m P et al (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51(4):268\u2013275","journal-title":"Prostate"},{"issue":"2","key":"4756_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/modpathol.3800034","volume":"17","author":"RS Saad","year":"2004","unstructured":"Saad RS et al (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17(2):197\u2013203","journal-title":"Mod Pathol"},{"issue":"11","key":"4756_CR21","first-page":"3410","volume":"7","author":"F Tanaka","year":"2001","unstructured":"Tanaka F et al (2001) Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7(11):3410\u20133415","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4756_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1309\/1KF54L6RB625556W","volume":"119","author":"J-P Dales","year":"2003","unstructured":"Dales J-P et al (2003) CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas: correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol 119(3):374\u2013380","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"4756_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1046\/j.1365-2141.2000.01869.x","volume":"108","author":"L Pierelli","year":"2000","unstructured":"Pierelli L et al (2000) CD34+\/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+\/CD38low\/\u2212 precursors. Br J Haematol 108(3):610\u2013620","journal-title":"Br J Haematol"},{"issue":"24","key":"4756_CR24","doi-asserted-by":"publisher","first-page":"15468","DOI":"10.1073\/pnas.202614899","volume":"99","author":"C-Z Chen","year":"2002","unstructured":"Chen C-Z et al (2002) Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci 99(24):15468\u201315473","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"4756_CR25","first-page":"688","volume":"133","author":"L Borges","year":"2019","unstructured":"Borges L et al (2019) Serial transplantation reveals a critical role for endoglin in hematopoietic stem cell quiescence. Blood J Am Soc Hematol 133(7):688\u2013696","journal-title":"Blood J Am Soc Hematol"},{"issue":"9","key":"4756_CR26","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1080\/10428194.2017.1416366","volume":"59","author":"V Cosimato","year":"2018","unstructured":"Cosimato V et al (2018) Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients. Leuk Lymphoma 59(9):2242\u20132245","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"4756_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.leu.2404142","volume":"20","author":"MG Della Porta","year":"2006","unstructured":"Della Porta MG et al (2006) Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 20(4):549\u2013555","journal-title":"Leukemia"},{"issue":"1","key":"4756_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-54767-x","volume":"9","author":"J Kauer","year":"2019","unstructured":"Kauer J et al (2019) CD105 (Endoglin) as negative prognostic factor in AML. Sci Rep 9(1):1\u201311","journal-title":"Sci Rep"},{"issue":"5","key":"4756_CR29","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4149\/neo_2014_071","volume":"61","author":"F Vrbacky","year":"2014","unstructured":"Vrbacky F et al (2014) Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. Neoplasma 61(5):585\u2013592","journal-title":"Neoplasma"},{"issue":"1","key":"4756_CR30","first-page":"24","volume":"14","author":"L Smolej","year":"2008","unstructured":"Smolej L et al (2008) Plasma levels of soluble endoglin have prognostic significance in patients with chronic lymphocytic leukemia. Transfuze Hematol Dnes 14(1):24\u201327","journal-title":"Transfuze Hematol Dnes"},{"issue":"25","key":"4756_CR31","first-page":"2745","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood J Am Soc Hematol 131(25):2745\u20132760","journal-title":"Blood J Am Soc Hematol"},{"issue":"4","key":"4756_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.0.CO;2-X","volume":"81","author":"DW Miller","year":"1999","unstructured":"Miller DW et al (1999) Elevated expression of endoglin, a component of the TGF-\u03b2-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 81(4):568\u2013572","journal-title":"Int J Cancer"},{"issue":"1","key":"4756_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12185-020-02875-0","volume":"112","author":"M M\u00e4rklin","year":"2020","unstructured":"M\u00e4rklin M et al (2020) CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation. Int J Hematol 112(1):57\u201364","journal-title":"Int J Hematol"},{"issue":"10","key":"4756_CR34","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/bloodadvances.2019001091","volume":"4","author":"A Manna","year":"2020","unstructured":"Manna A et al (2020) Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Adv 4(10):2143\u20132157","journal-title":"Blood Adv"},{"issue":"3","key":"4756_CR35","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1046\/j.1365-2141.1997.792715.x","volume":"97","author":"L Lagneaux","year":"1997","unstructured":"Lagneaux L et al (1997) Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGF-\u03b2 receptors. Br J Haematol 97(3):612\u2013620","journal-title":"Br J Haematol"},{"issue":"11","key":"4756_CR36","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.1073\/pnas.94.11.5877","volume":"94","author":"JF DeCoteau","year":"1997","unstructured":"DeCoteau JF et al (1997) Loss of functional cell surface transforming growth factor \u03b2 (TGF-\u03b2) type 1 receptor correlates with insensitivity to TGF-\u03b2 in chronic lymphocytic leukemia. Proc Natl Acad Sci 94(11):5877\u20135881","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"4756_CR37","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/jcp.20311","volume":"204","author":"FJ Blanco","year":"2005","unstructured":"Blanco FJ et al (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-\u03b2 receptor complex. J Cell Physiol 204(2):574\u2013584","journal-title":"J Cell Physiol"},{"issue":"7","key":"4756_CR38","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/intimm\/dxh272","volume":"17","author":"CB Schmidt-Weber","year":"2005","unstructured":"Schmidt-Weber CB et al (2005) TGF-\u03b2 signaling of human T cells is modulated by the ancillary TGF-\u03b2 receptor endoglin. Int Immunol 17(7):921\u2013930","journal-title":"Int Immunol"},{"issue":"Suppl 1","key":"4756_CR39","first-page":"158","volume":"33","author":"S Attia","year":"2015","unstructured":"Attia S et al (2015) A phase 1b dose-escalation study of TRC105 (anti-Endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). J Clin Oncol 33(Suppl 1):158","journal-title":"J Clin Oncol"},{"issue":"1","key":"4756_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.clgc.2016.05.010","volume":"15","author":"AB Apolo","year":"2017","unstructured":"Apolo AB et al (2017) A phase II clinical trial of TRC105 (anti-endoglin antibody) in adults with advanced\/metastatic urothelial carcinoma. Clin Genitourin Cancer 15(1):77\u201385","journal-title":"Clin Genitourin Cancer"},{"issue":"16","key":"4756_CR41","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-16-3171","volume":"23","author":"AG Duffy","year":"2017","unstructured":"Duffy AG et al (2017) Phase I and preliminary phase II study of TRC105 in combination with sorafenib in hepatocellular carcinoma. Clin Cancer Res 23(16):4633\u20134641","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04756-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T16:29:37Z","timestamp":1674491377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04756-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["4756"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04756-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}